Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Optom Vis Sci ; 92(5): e97-e105, 2015 May.
Article in English | MEDLINE | ID: mdl-25871873

ABSTRACT

PURPOSE: To present a case of neovascular age-related macular degeneration treated with aflibercept intravitreal injections after bilateral bevacizumab injections, administered on separate dates, resulted in bilateral iritis. CASE REPORT: A 73-year-old woman with a previous history of two episodes of nongranulomatous iritis in her right eye that was believed to be associated with her systemic diagnosis of rheumatoid arthritis was treated with intravitreal bevacizumab injections for bilaterally occurring neovascular age-related macular degeneration. Initial bevacizumab injections in each eye administered sequentially over a week's time resulted in immediate-onset nongranulomatous iritis in each eye. Subsequent intravitreal injections of aflibercept were administered, and therapeutic benefit was achieved without occurrence of iritis. CONCLUSIONS: In cases where intravitreal bevacizumab results in anterior uveitis, aflibercept may be a safe alternative therapeutic choice for the treatment of neovascular age-related macular degeneration.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Iritis/chemically induced , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Wet Macular Degeneration/drug therapy , Aged , Angiogenesis Inhibitors/therapeutic use , Bevacizumab , Drug Substitution , Female , Humans , Intravitreal Injections , Iritis/diagnosis , Retrospective Studies , Tomography, Optical Coherence , Treatment Outcome , Visual Acuity , Wet Macular Degeneration/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...